Apptly Closes First Tranche of Non-Brokered Private Placement
The financing adds cash while issuing common shares and warrants exercisable at $0.25 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apptly Health Technologies (APTHF) completed the first tranche of its non-brokered private placement, raising gross proceeds of $726,450.
The company issued 5,811,600 units at $0.125 each, comprising one common share and one share purchase warrant. Each warrant permits purchase of one share at $0.25 for twelve months following October 6, 2026, subject to acceleration. If shares close at or above $0.35 for thirty consecutive trading days, Apptly may shorten the warrant term to thirty days after an announcement.
Apptly paid $2,975 in finder's fees and issued 23,800 broker warrants, exercisable at $0.25 for twelve months after closing, subject to acceleration. Interim CEO and director Paula Muto subscribed for $133,950.00 of units; an existing 10% shareholder subscribed for $100,000.00. Apptly expects a second tranche to close in the coming weeks, subject to customary closing conditions and any required regulatory approvals.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFirst-tranche closing raised $726,450 in gross proceeds.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Apptly expects a second tranche in the coming weeks, subject to closing conditions and required regulatory approvals.
Negative
- Moderate point5,811,600 units at $0.125 each add common shares and warrants, diluting existing holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Unit warrants allow additional shares at $0.25 for twelve months after October 6, 2026, subject to acceleration.
- Minor pointFinder's fees cost Apptly $2,975.
- Minor point. Forward-looking: it has not happened yet and may not happen.23,800 broker warrants permit additional shares at $0.25 for twelve months after closing, subject to acceleration.
- Minor point. Forward-looking: it has not happened yet and may not happen.Unit warrants may expire thirty days after notice following thirty consecutive trading days closing at or above $0.35.
News Explained
The completed share issuance reduces existing holders’ ownership percentages; additional warrant dilution depends on exercise, while proceeds are primarily for working capital.
Apptly completed the first tranche, issuing one common share per unit; those shares increase the share count and reduce existing holders’ percentage ownership.
Each unit also carries a warrant for one further share, so additional issuance—and dilution—would depend on exercise. Net proceeds are primarily for general working capital.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company") is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement offering (the "Offering"), issuing 5,811,600 units of the Company (the "Units") at a price equal to
Each Unit is comprised of one common share of the Company (each, a "Share") and one common share purchase warrant of the Company (each, a "Warrant"). Each Warrant is exercisable to acquire one (1) Share at an exercise price of
The net proceeds raised under the Offering will be primarily used for general working capital purposes.
In connection with closing of the first tranche of the Offering, the Company has paid finder's fees totaling
The securities issued under the Offering are subject to a hold period of four months and one day from the First Tranche Closing Date in accordance with applicable Canadian securities laws and such other further restrictions as may apply under foreign securities laws. The Company expects to close a second tranche of the Offering in the coming weeks, subject to customary closing conditions and any required regulatory approvals.
MI 61-101
Paula Muto, interim Chief Executive Officer and a director of the Company, subscribed for an aggregate of 1,071,600 Units for gross proceeds of
The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Apptly Health Technologies Corp.
Apptly Health Technologies Corp. operates UberDoc, a direct-pay healthcare marketplace that connects patients directly with board-certified specialists at transparent, upfront prices, with no referral requirements, no insurance barriers, and no surprise bills. With more than 5,000 specialist physicians and clinicians across 55-plus specialties in all 50 states, the platform provides patients with faster access to care while enabling physicians to expand patient access and grow their practices. The Company was founded by Dr. Paula M. Muto, M.D.
Forward-Looking Statements
This news release contains "forward-looking statements" or "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable securities legislation. Generally, forward-looking statements can be identified by the use of terminology such as "seek", "expect", "anticipate", "budget", "plan", "estimate", "continue", "forecast", "intend", "believe", "predict", "potential", "target", "may", "could", "would", "might", "will" and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved" (including negative variations). Forward-looking statements in this release include, but are not limited to, statements regarding the anticipated benefits and impacts of the Offering, statements regarding the anticipated use of proceeds from the Offering and the Company's future operations and business prospects. All statements, other than statements of historical fact, are forward-looking statements and are based on the assumptions, expectations, estimates and projections as of the date of this news release. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein, including, without limitation, risks that the anticipated use of proceeds from the Offering and the benefits and impacts of the Offering not being as anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release
Contacts
Investor Relations / Media
Meghna Deshraj
meghna@uber-docs.com
973-369-8052
apptlyhealthtech.com
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/317800
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Apptly raise in its first private placement tranche, and at what price?
Apptly raised $726,450 in gross proceeds by issuing 5,811,600 units at $0.125 each. Each unit contains one common share and one warrant to purchase an additional share at $0.25.
Which insiders participated in Apptly's private placement?
Interim CEO and director Paula Muto subscribed for 1,071,600 units for $133,950.00, and an existing 10% shareholder subscribed for 800,000 units for $100,000.00. Both subscriptions constitute related-party transactions under MI 61-101, the rules protecting minority shareholders in certain transactions.
Why was Apptly's insider participation exempt from valuation and minority approval requirements?
The issuance qualified for a formal valuation exemption because Apptly's shares are listed on the CSE and a minority approval exemption because the fair market value was less than $2,500,000. The exemptions fall under Subsections 5.5(b) and 5.7(1)(b), respectively, of MI 61-101.